MK-6913: Development discontinued

Merck discontinued development of MK-6913 to treat hot flashes after interim data from the first stage of a double-blind, placebo- and active-controlled, international Phase II trial in postmenopausal women showed that the compound missed undisclosed, pre-defined efficacy criteria for advancing to the second stage of the trial. Karo Bio said that partner Merck is evaluating its options for future studies involving MK-6913. ...